Finoriq research workspace

Artiva Biotherapeutics, Inc. (ARTV) Insider Transactions & Form 4 Activity

Track insider acquisitions, dispositions, options, RSUs, and Form 4 activity for Artiva Biotherapeutics, Inc. (ARTV).

Company Snapshot

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.

Company

Artiva Biotherapeutics, Inc. (ARTV)

Ticker

ARTV

Market Cap

$229.9M

Latest Price

$9.30

Industry

Biotech & Pharma

Open company research

Artiva Biotherapeutics, Inc. (ARTV) Recent Insider Transactions

Recent market insider transaction records indexed for Artiva Biotherapeutics, Inc. (ARTV).

Live data loads in the app

This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.